S419
Clinical - Gynaecological
ESTRO 2026
trials. J Clin Oncol. 2008;26(35):5802- 12.2) Ward GA, Lewis EJ, Ahn JS, Johnson CN, Lyons JF, Martins V, et al. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFalpha- Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Mol Cancer Ther. 2018;17(7):1381-91. Keywords: Tolinapant, Chemoradiation, Phase Ib Impact of primary radiotherapy on the psychosocial well-being of patients with locally advanced cervical cancer (IMPRaCC study). Sofia Spampinato 1 , Sezen Kutluyer 1 , Saliha Almaz 1 , Nicoline Schuur 2 , Jobert Sturm 3 , Miranda EMC Christianen 1 , Jan Willem Mens 1 , Helena C van Doorn 2 , Henrike Westerveld 1 1 Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Digital Poster 1288 2 Department of Gynaecologic Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 3 Department of Advanced Nursing Practice, Rotterdam University of Applied Sciences, Rotterdam, Netherlands Purpose/Objective: Current standard of care for locally advanced cervical cancer (LACC) consists of external beam radiotherapy (EBRT), concurrent chemotherapy, and image-guided brachytherapy. Treatment, especially brachytherapy, can be physically and emotionally demanding for patients. The IMPRaCC study (Impact of primary Radiotherapy on the psychosocial well-being of patients with LACC) aimed to investigate functioning, quality of life, and symptoms during and after radiotherapy, and identify risk factors for worse psycho-social well- being. Material/Methods: EORTC-C30 questionnaires collected in a monocentre LACC cohort treated between
January 2019 and December 2024 were analysed. Patients received EBRT (45Gy/25 fractions) and brachytherapy (21-28 Gy/3-4 HDR fractions). Questionnaires were collected at baseline, during treatment at two, five and eight weeks, and every three months up to two years of follow-up. Patients who completed questionnaires at baseline and at least twice in follow-up were included in the analysis. Linear-mixed models evaluated changes in EORTC-C30 scores from baseline. Scores were also compared to a healthy reference population (RP)1. Deteriorations/improvements were defined according to EORTC-C30 guidelines2. Logistic regression identified factors associated with deteriorations compared to baseline in emotional (EF) and social functioning (SF) and fatigue during treatment and in follow-up. Deteriorations were defined “persistent” if reported in ≥ 50% of assessments between 6– 24 months follow-up3. Results: Of 313 LACC patients, 142 met the inclusion criteria and were included. Median age was 49 years; most patients were in a relationship (74%) and had no psychiatric history (70%). Psychological support during treatment was provided to 30%. Brachytherapy was usually delivered in 3 fractions (81%), and 13% stayed overnight with applicator in situ. EF and SF were impaired at baseline and during treatment compared to the RP but improved in follow-up and approached normative level (Figure 1). Deteriorations in EF, SF and fatigue were more frequent during treatment (18.6%, 48.8%, 62.8%) than follow-up (10.4%, 25%, 34.4%). Psychiatric history was associated with worse SF during treatment, while being in a relationship and psychological support were protective factors. Brachytherapy delivered in four vs. three fractions was associated with deteriorations in EF, SF and fatigue (Table1).
Made with FlippingBook - Share PDF online